Sunrest Lifescience Share Price Today

Sunrest Lifescience wins Rs 9.22 crore order from Gujarat Medical Services Corporation Limited

**Order type and value:** Confirmed order (TYPE A) worth Rs 9.22 crore from Gujarat Medical Services Corporation Limited, to be executed through subsidiary Hetvi Lifesciences Private Limited, disclosed on 20 August 2026. **Scale context:** Sunrest Lifescience is an SME-classified pharmaceuticals company with a market cap of Rs 72.35 crore as of 20 Aug 2026; the Rs 9.22 crore order is material relative to company scale. **Book-to-bill context:** Consolidated trailing twelve-month revenue is reported as Rs 0.0 crore in available data, preventing computation of book-to-bill or backlog coverage ratios; no prior order history is available for the last three fiscal quarters. **Execution trend:** Quarterly revenue and profitability data are unavailable; standalone annual revenue grew 12.3% in FY25 and 19.5% in FY24, but quarterly execution trends cannot be assessed from available inputs. **Key risk observation:** The subsidiary execution structure, absence of historical order inflow data, and high volatility in standalone profit growth (786.0% in FY25 after -89.0% in FY24) are factors investors should assess alongside the working capital position, for which balance sheet data is currently unavailable.

Sunrest Lifescience announces rights issue of 42.91 lakh shares at ₹35

Sunrest Lifescience Limited approved a rights issue of 42,91,200 shares at ₹35 each, doubling its outstanding capital. The record date is August 10, 2026, with the issue open from August 18 to September 02, 2026. Shareholders receive a 1:1 entitlement ratio.

Sunrest Lifescience board approves raising Rs.15.10 crores via rights issue

Sunrest Lifescience's board approved raising up to Rs.15.10 crores via a rights issue of equity shares with a face value of Rs.10 each. The Draft Letter of Offer was approved, but the issue price, ratio, and record date are pending. The proposal is subject to NSE approval and relevant SEBI regulations.

Sunrest Lifescience reports FY25 assets of ₹3515.71 lacs

Sunrest Lifescience Limited reported audited annual results for FY25, showing total assets of ₹3515.71 lacs. Reserves increased to ₹1189.40 lacs, while trade receivables stood at ₹1901.10 lacs. Long-term borrowings rose to ₹408.28 lacs.

Sunrest Lifescience reports consolidated net profit of ₹411.63 lakh in FY26

Sunrest Lifescience reported a consolidated net profit of ₹411.63 lakh for FY26, up from ₹200.56 lakh in the previous year, with revenue rising to ₹7083.29 lakh. Standalone net profit increased to ₹308.86 lakh. The board approved the audited financial results and appointed M/S. VRCA & Associates as internal auditor for FY27.